Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2000 May 16;162(10):1441–1447.

Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias

J G Fodor 1, J J Frohlich 1, J J Genest Jr 1, P R McPherson 1
PMCID: PMC1232457  PMID: 10834048

Full Text

The Full Text of this article is available as a PDF (258.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992 Sep 15;70(7):733–737. doi: 10.1016/0002-9149(92)90550-i. [DOI] [PubMed] [Google Scholar]
  2. Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J. T., Kaplan C., Zhao X. Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 Nov 8;323(19):1289–1298. doi: 10.1056/NEJM199011083231901. [DOI] [PubMed] [Google Scholar]
  3. Buchwald H., Varco R. L., Matts J. P., Long J. M., Fitch L. L., Campbell G. S., Pearce M. B., Yellin A. E., Edmiston W. A., Smink R. D., Jr Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med. 1990 Oct 4;323(14):946–955. doi: 10.1056/NEJM199010043231404. [DOI] [PubMed] [Google Scholar]
  4. Cashin-Hemphill L., Mack W. J., Pogoda J. M., Sanmarco M. E., Azen S. P., Blankenhorn D. H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990 Dec 19;264(23):3013–3017. [PubMed] [Google Scholar]
  5. Castelli W. P., Garrison R. J., Wilson P. W., Abbott R. D., Kalousdian S., Kannel W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986 Nov 28;256(20):2835–2838. [PubMed] [Google Scholar]
  6. Després J. P. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res. 1998 Apr;6 (Suppl 1):8S–17S. doi: 10.1002/j.1550-8528.1998.tb00683.x. [DOI] [PubMed] [Google Scholar]
  7. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Stein E. A., Kruyer W., Gotto A. M., Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615–1622. doi: 10.1001/jama.279.20.1615. [DOI] [PubMed] [Google Scholar]
  8. Frohlich J., Fodor G., McPherson R., Genest J., Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. Can J Cardiol. 1998 Apr;14 (Suppl A):17A–21A. [PubMed] [Google Scholar]
  9. Grundy S. M., Balady G. J., Criqui M. H., Fletcher G., Greenland P., Hiratzka L. F., Houston-Miller N., Kris-Etherton P., Krumholz H. M., LaRosa J. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation. 1997 May 6;95(9):2329–2331. doi: 10.1161/01.cir.95.9.2329. [DOI] [PubMed] [Google Scholar]
  10. Grundy S. M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998 Feb 26;81(4A):18B–25B. doi: 10.1016/s0002-9149(98)00033-2. [DOI] [PubMed] [Google Scholar]
  11. Grundy S. M., Pasternak R., Greenland P., Smith S., Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999 Sep 28;100(13):1481–1492. doi: 10.1161/01.cir.100.13.1481. [DOI] [PubMed] [Google Scholar]
  12. Haffner S. M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229–234. doi: 10.1056/NEJM199807233390404. [DOI] [PubMed] [Google Scholar]
  13. Haskell W. L., Alderman E. L., Fair J. M., Maron D. J., Mackey S. F., Superko H. R., Williams P. T., Johnstone I. M., Champagne M. A., Krauss R. M. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994 Mar;89(3):975–990. doi: 10.1161/01.cir.89.3.975. [DOI] [PubMed] [Google Scholar]
  14. Hopkins P. N., Wu L. L., Hunt S. C., James B. C., Vincent G. M., Williams R. R. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2783–2792. doi: 10.1161/01.atv.17.11.2783. [DOI] [PubMed] [Google Scholar]
  15. Kane J. P., Malloy M. J., Ports T. A., Phillips N. R., Diehl J. C., Havel R. J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990 Dec 19;264(23):3007–3012. [PubMed] [Google Scholar]
  16. Kannel W. B., D'Agostino R. B., Cobb J. L. Effect of weight on cardiovascular disease. Am J Clin Nutr. 1996 Mar;63(3 Suppl):419S–422S. doi: 10.1093/ajcn/87.6.1602. [DOI] [PubMed] [Google Scholar]
  17. Kronenberg F., Kronenberg M. F., Kiechl S., Trenkwalder E., Santer P., Oberhollenzer F., Egger G., Utermann G., Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999 Sep 14;100(11):1154–1160. doi: 10.1161/01.cir.100.11.1154. [DOI] [PubMed] [Google Scholar]
  18. LaRosa J. C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999 Dec 22;282(24):2340–2346. doi: 10.1001/jama.282.24.2340. [DOI] [PubMed] [Google Scholar]
  19. Ornish D., Brown S. E., Scherwitz L. W., Billings J. H., Armstrong W. T., Ports T. A., McLanahan S. M., Kirkeeide R. L., Brand R. J., Gould K. L. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990 Jul 21;336(8708):129–133. doi: 10.1016/0140-6736(90)91656-u. [DOI] [PubMed] [Google Scholar]
  20. Pedersen T. R., Olsson A. G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyörälä K. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation. 1998 Apr 21;97(15):1453–1460. doi: 10.1161/01.cir.97.15.1453. [DOI] [PubMed] [Google Scholar]
  21. Pitt B., Waters D., Brown W. V., van Boven A. J., Schwartz L., Title L. M., Eisenberg D., Shurzinske L., McCormick L. S. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999 Jul 8;341(2):70–76. doi: 10.1056/NEJM199907083410202. [DOI] [PubMed] [Google Scholar]
  22. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998 Oct;19(10):1434–1503. doi: 10.1053/euhj.1998.1243. [DOI] [PubMed] [Google Scholar]
  23. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  24. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  25. Watts G. F., Lewis B., Brunt J. N., Lewis E. S., Coltart D. J., Smith L. D., Mann J. I., Swan A. V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet. 1992 Mar 7;339(8793):563–569. doi: 10.1016/0140-6736(92)90863-x. [DOI] [PubMed] [Google Scholar]
  26. Wilson P. W., D'Agostino R. B., Levy D., Belanger A. M., Silbershatz H., Kannel W. B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 May 12;97(18):1837–1847. doi: 10.1161/01.cir.97.18.1837. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES